MedTrace Logo

SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

NCT05461170 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2026-06-26

No results posted yet for this study

Summary

This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy

Conditions

  • Hepatitis D, Chronic

Interventions

DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

DRUG

NRTI

NRTI given orally.

Sponsors & Collaborators

  • Vir Biotechnology, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-17
Primary Completion
2031-11-30
Completion
2032-05-31
FDA Drug
Yes

Countries

  • Bulgaria
  • France
  • Germany
  • Italy
  • Moldova
  • Netherlands
  • New Zealand
  • Romania
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461170 on ClinicalTrials.gov